|
|
ALPHAGAN® P 0.1, approved by the U.S. Food and Drug Administration (FDA) in 2005, and ALPHAGAN® P 0.15, approved by the FDA in 2001, are indicated to lower IOP in patients with open-angle glaucoma and ocular hypertension. They are improved formulations of ALPHAGAN® developed to further minimize drug exposure while maintaining the drug's favorable efficacy profile.
|